Abstract:Background:Although cigarette smoking is a risk factor for multiple disorders, it has long been thought to protect against Parkinson's disease (PD). Quantitative susceptibility mapping (QSM) is a novel magnetic resonance imaging (MRI)-based technique for assessing iron accumulation in vivo that has been widely applied in PD studies. This study aimed to investigate how cigarette smoking affects clinical performance of PD using quantified iron deposition as a proxy for PD pathology.Methods:In this observational study, we enrolled 35 male PD patients and 47 male healthy controls (HCs) and divided them into four groups. We performed an enhanced T2 star-weighted angiography (ESWAN) MRI sequence to measure the iron content of the nuclei within the nigrostriatal pathway. With the age and total intracranial volume (TIV) controlled as covariates, we performed inter-group comparisons of QSM values and moderation analyses for PD patients using smoking status and the smoking index (SI), respectively, as moderator variables.Results:The 2-way multivariate analysis of covariance (MANCOVA) results showed higher QSM values in the left red nucleus (P=0.024) in PD patients compared with those in HCs, and in the bilateral globi pallidi [left/right (L/R): P=0.009/0.003], substantia nigra pars compacta (SNc; L/R: P=0.001/0.037), and right substantia nigra pars reticulata (SNr; P=0.002) in non-smokers compared with smokers, with no marked interaction effect between PD and smoking status observed when applying the Bonferroni adjustment for multiple comparisons. Using cigarette smoking status and the SI as separate moderator variables, the moderation was shown up by a significant interaction effect in a disordinal and double-edged form. In our results, smoking-moderated protection for PD movement deficits emerged when PD was progressed. Among the affected deep brain nuclei, the nuclei most moderated by the impact of cigarette smoking on the interaction between brain iron and PD symptoms were the thalamus [smoking status associated with the Unified Parkinson's Disease Rating Scale (UPDRS) total score, P=0.04 (L); rigidity, P=0.03 (L); SI associated with UPDRS-III, P (L/R) =0.049/0.0497; rigidity, P (L/R) =0.01/0.02; bradykinesia, P (L/R) =0.048/0.04], the right red nucleus (SI associated with rigidity, P=0.04; bradykinesia, P=0.02), and the left SNc [smoking status associated with the Hoehn and Yahr (H&Y) stage, P=0.01].Conclusions:This was the first study investigating the impacts of current cigarette smoking on PD using quantified iron deposition. Our study confirmed the protective role of cigarette smoking against PD, consistent with the findings of previous studies. Furthermore, neuroprotection was present only when the PD pathology had progressed to a certain extent. In the interaction between iron deposition and clinical PD symptoms, our findings suggest that the thalamus, red nucleus, and SNc are likely to be the most affected nuclei moderated by cigarette smoking.

Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson's disease patients and healthy controls

Association of Coffee Consumption and Striatal Dopamine Transporter Binding in Patients with Parkinson’s Disease and Healthy Controls

Association between cigarette smoking and Parkinson's disease: a neuroimaging study

Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease

Neural Substrates for the Association Between Cigarette Smoking and Parkinson's Disease

Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese

Coffee and Parkinson's disease

Does Drinking Coffee Reduce the Incidence of Parkinson's Disease?

Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms

The Protective Role of Cigarette Smoking Against Parkinson’s Disease Via Moderation of the Interaction Between Iron Deposition in the Nigrostriatal Pathway and Clinical Symptoms

Effect of Coffee against MPTP-Induced Motor Deficits and Neurodegeneration in Mice Via Regulating Gut Microbiota

Dose–response Meta‐analysis on Coffee, Tea and Caffeine Consumption with Risk of Parkinson's Disease

Levodopa Imparts a Normalizing Effect on Default-Mode Network Connectivity in Non-Demented Parkinson’s Disease

Iron-related Nigral Degeneration Influences Functional Topology Mediated by Striatal Dysfunction in Parkinson's Disease.

Habitual Coffee Consumption and Risk of Cognitive Decline/dementia: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.

Tea consumption and risk of Parkinson's disease: A meta-analysis

Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk

Associations between different coffee types, neurodegenerative diseases, and related mortality: findings from a large prospective cohort study

Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use.

Coffee Consumption and Risk of Stroke: A Mendelian Randomization Study

Potential Benefits of Coffee Consumption on Improving Biomarkers of Oxidative Stress and Inflammation in Healthy Individuals and Those at Increased Risk of Cardiovascular Disease